CLDX
Celldex Therapeutics Inc
Price:  
20.66 
USD
Volume:  
598,699.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

CLDX WACC - Weighted Average Cost of Capital

The WACC of Celldex Therapeutics Inc (CLDX) is 6.6%.

The Cost of Equity of Celldex Therapeutics Inc (CLDX) is 9.55%.
The Cost of Debt of Celldex Therapeutics Inc (CLDX) is 5.00%.

Range Selected
Cost of equity 7.10% - 12.00% 9.55%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 5.4% - 7.8% 6.6%
WACC

CLDX WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.7 1.27
Additional risk adjustments 0.0% 0.5%
Cost of equity 7.10% 12.00%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 5.4% 7.8%
Selected WACC 6.6%

CLDX's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for CLDX:

cost_of_equity (9.55%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.7) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.